Kymera Therapeutics (KYMR) Gets a Buy from Truist Financial
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Kymera Therapeutics with a price target of $80. UBS's Eliana Merle also issued a Buy rating, while TR | OpenAI reiterated a Hold rating on November 15. Devarakonda, focusing on the Healthcare sector, has an average return of 13.9% and a 54.98% success rate on recommended stocks.
Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Kymera Therapeutics today and set a price target of $80.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Devarakonda covers the Healthcare sector, focusing on stocks such as Scholar Rock Holding, Terns Pharmaceuticals, and Nurix Therapeutics. According to TipRanks, Devarakonda has an average return of 13.9% and a 54.98% success rate on recommended stocks.
In addition to Truist Financial, Kymera Therapeutics also received a Buy from UBS’s Eliana Merle in a report issued today. However, on November 15, TR | OpenAI – 4o reiterated a Hold rating on Kymera Therapeutics (NASDAQ: KYMR).
